RE: Our current position.23 May 2025 08:02
Thanks Max
This bit confuses me though “ Among the 23 evaluable patients treated daily with GaM, the average overall survival was about 14 months from the start of therapy, a positive result compared to current therapies. The treatment was safe and well tolerated. Although progression-free survival (PFS) remained similar to standards (about 2 months), the overall survival data suggests a potential benefit in disease control.”
The 14 and 2 months quoted don’t seem to match with the figures quoted by IB. Not sure if I am reading this wrong.
Anyway before semantic worries I have forgot, have a good long weekend everybody.
Thanks